MaxCyte
Business Services · Maryland, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
9713 Key West Ave, Rockville, Maryland, ...Phone Number
(301) 944-1700Website
www.maxcyte.comRevenue
$32.3 MillionStock Symbol
MXCTIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs.Explore more
MaxCyte Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MaxCyte your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
MaxCyte, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at MaxCyte
Earning: See what the market has to say on MaxCyte recently announced quarterly report
Funding: Get notified immidiatlly once MaxCyte has new funding data
Check if MaxCyte has recently received funding, and reach out quickly before it becomes old news!
Check out if MaxCyte is spiking on competitors!
Product Launch: Get notified when MaxCyte launches new products
Click to see if MaxCyte had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined MaxCyte as Masked Content
Find 2 more new buyers
Compare Similar Companies to MaxCyte
Compare insights from companies similar to MaxCyte, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MaxCyte is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
MaxCyte is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about MaxCyte.
MaxCyte financials insights
Gather financial insights about MaxCyte, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2003
Series A
$8M
2004
Series B
$10.7M
2016
Stock Offering
$14.4M
2019
Share Placement
$12.3M
2020
Debt
$1M
Share Placement
$30.9M
MaxCyte Tech Stack
A closer look at the technologies used by MaxCyte
Most Recent Scoops
Person-Based
Earnings, Finance
Hiring Plans
MaxCyte has more open roles in Engineering & Technical than it has had at any time in the past 12 months.
Hiring Plans
Hiring Plans
MaxCyte has more open roles in Finance than it has had at any time in the past 12 months.
Hiring Plans
Open Position
Open Position
MaxCyte News & Media
MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript
MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call May 12, 2026 4:30 PM EDTCompany ParticipantsEric AbdelMaher Masoud - President, CEO & Executive...MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenueMaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2026 after the U.S. market close on Tuesday, May 12th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. EasternMaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 375,000 shares of MaxCyte’s common stock and a service-based restricted st
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MaxCyte
Sign Up For FreeTo access detailed company insights
MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs.... Read More
